AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05268835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalacin C
Description: The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
Study NCT04520178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan 100 MG
Description: 100mg combined with 50mg carbidopa
Study NCT04520178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan
Description: 50mg combined with 50mg carbidopa
Study NCT04520178 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Carbidopa
Description: 50mg
Study NCT04520178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa
Description: 50mg
Study NCT04520178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03716687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic negative pressure wound dressing after laparotomy
Description: Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
Study NCT02259881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02259881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS), single i.v. bolus
Description: Endotoxin derived from E. coli bacteria, used for activation of coagulation
Study NCT01159821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 31001074/paroxetine
Description: 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
Study NCT06152692 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SHAM Continuous positive airway pressure
Description: Placebo treatment
Study NCT06152692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
Study NCT01285752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK106-001616
Study NCT01285752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Study NCT04307953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530 Difumarate
Description: AZD0530 for the duration of the trial
Study NCT04307953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo during 6 month RCT, AZD0530 thereafter
Study NCT02259881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide (LPS), single i.v. bolus
Description: Endotoxin derived from E. coli bacteria, used for activation of coagulation
Study NCT03622944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technic
Description: post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
Study NCT03622944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Friction Massage
Description: deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
Study NCT03622944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: spinal stabilization exercise were applied three sessions in a week totally six weeks.
Study NCT00920946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 20 mg Dimebon orally TID
Study NCT00920946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally TID
Study NCT00524667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid & fludarabine
Description: valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
Study NCT01061645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOC31-PE
Description: Immunotoxines
Study NCT04377789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin Prophylaxis
Description: a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
Study NCT04377789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin Treatment
Description: a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
Study NCT01510548 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab injections for acute disc prolapse patients
Description: see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
Study NCT01510548 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab injections for acute disc prolapse patients
Description: see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
Study NCT02509299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program 1
Description: The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
Study NCT02509299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program 2
Description: COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises
Study NCT02509299 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard medical treatment
Description: The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Study NCT00889369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
Study NCT01531829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Description: Low dose (50mg/2h) rt-PA plus LMWH
Study NCT01531829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin
Description: 0.1ml/10kg,q12h,5-7 days
Study NCT03788304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive ventilation
Description: conventional NIV
Study NCT03788304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: HFNC ventilation
Study NCT00737750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab
Description: Program of NMES 3 times per day, five days per week for 12 weeks.
Study NCT00737750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poli-Stim
Description: Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
Study NCT00737750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Voluntary quadriceps muscle contractions.
Study NCT00637650 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments
Study NCT00637650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment
Study NCT05393843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids, anthocyanins and alpha-cyclodextrins
Description: administration for 12 weeks
Study NCT05393843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: 12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
Study NCT05393843 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: diet
Description: 12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
Study NCT05393843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
Study NCT01546376 — intervention group
Intervention type: RADIATION
Intervention: Radiation therapy
Description: External photon beam radiation therapy dosage 4000-7000 CGy
Study NCT01546376 — intervention group
Intervention type: OTHER
Intervention: Venepuncture
Description: Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
Study NCT04275206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harkány medicinal water
Description: The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.
Study NCT04275206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tap water (placebo control)
Description: The control group is treated with tap water.
Study NCT04289597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Distance between hyoid bone-skin (DSHB)
Description: Distance between hyoid bone-skin
Study NCT04289597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vocal cord anterior commissura-skin distance (DSAC)
Description: Vocal cord anterior commissura-skin distance
Study NCT04289597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: minimum distance of the trachea to the skin at the level of suprasternal notch
Description: Distance of the trachea to the skin at the level of suprasternal notch
Study NCT04289597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid isthmus-skin distance (DSI)
Description: Thyroid isthmus-skin distance
Study NCT04289597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin-epiglottic distance (DSE)
Description: Skin-epiglottic distance
Study NCT04257552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Beyond Pregnancy
Description: Web-based application grounded in tenants of behavioral economics.
Study NCT04257552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Scheduled Postpartum Visit
Description: Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
Study NCT04257552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
Study NCT00852423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
Study NCT00852423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Description: MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
Study NCT00852423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine
Description: AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
Study NCT00852423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
Study NCT06100107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy exercise
Description: Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
Study NCT02256189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Sitagliptin 100 mg daily
Study NCT04012333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLIMEL 7,6%E / PeriOLIMEL 2,5%E
Description: OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
Study NCT03552289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
Description: The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Study NCT03552289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional angioplasty balloon catheters
Description: Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
Study NCT01934868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolotherapy solution of 20% dextrose
Description: After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
Study NCT01934868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
Study NCT01845519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Email
Description: Participants will receive tailored emails.
Study NCT01845519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Email
Description: Participants will receive targeted emails.
Study NCT04296604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Study NCT04296604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Study NCT01769612 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT04693806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous CO2 Level
Description: Embryos will be cultured in a single, continuous CO2 setting
Study NCT02561676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 1
Description: The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
Study NCT02561676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 2
Description: The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
Study NCT02443155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
Study NCT02443155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
Study NCT02443155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
Study NCT02443155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
Study NCT02443155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
Study NCT02443155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
Study NCT01059890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefotaxime
Study NCT01059890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Study NCT01059890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Study NCT01059890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfocine
Study NCT04261283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Circuit Training will be consisting of:~1. Habituation Exercises~2. Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~3. Exercises to improve Saccade Latency.~4. Adaptation Exercises~5. Substitution Exercises~6. Postural Control Exercises~7. General Conditioning Activities~8. Cawthorne-Cooksey Exercises~9. Ocular Motor Exercises~10. Gait Exercises~11. Treatment to Decrease Sensitivity to Motion in the Environment
Study NCT04261283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
Study NCT01976624 — intervention group
Intervention type: DRUG
Intervention: bimatoprost/timolol
Description: Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.